Skip to Content
Merck
CN

GF80139438

Bismuth

foil, not light tested, 50x50mm, thickness 0.05mm, permanent polyester support, 99.97%

Synonym(s):

Bismuth, BI000190

Sign Into View Organizational & Contract Pricing

Select a Size

About This Item

Empirical Formula (Hill Notation):
Bi
CAS Number:
7440-69-9
Molecular Weight:
208.98
MDL number:
MFCD00134033
UNSPSC Code:
12141706
PubChem Substance ID:
329811993
NACRES:
NA.23

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

vapor pressure

<0.1 mmHg ( 20 °C)

Assay

99.97%

form

foil

manufacturer/tradename

Goodfellow 801-394-38

resistivity

129 μΩ-cm, 20°C

size × thickness

50 x 50 mm × 0.05 m

bp

1560 °C (lit.)

mp

271 °C (lit.)

density

9.8 g/mL at 25 °C (lit.)

SMILES string

[Bi]

InChI

1S/Bi

InChI key

JCXGWMGPZLAOME-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

General description

For updated SDS information please visit www.goodfellow.com.

Legal Information

Product of Goodfellow

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Alexander C Ford et al.
World journal of gastroenterology, 14(48), 7361-7370 (2008-12-26)
To assess the safety of bismuth used in Helicobacter pylori (H pylori) eradication therapy regimens. We conducted a systematic review and meta-analysis. MEDLINE and EMBASE were searched (up to October 2007) to identify randomised controlled trials comparing bismuth with placebo
Hongyan Li et al.
Current opinion in chemical biology, 16(1-2), 74-83 (2012-02-11)
Bismuth has been used in medicine for over two centuries for the treatment of various diseases, in particular for gastrointestinal disorders, owing to its antimicrobial activity. Recent structural characterization of bismuth drugs provides an insight into assembly and pharmacokinetic pathway
Javier P Gisbert et al.
Helicobacter, 10(3), 157-171 (2005-05-21)
To systematically review the Helicobacter pylori eradication efficacy with ranitidine bismuth citrate (RBC) and two antibiotics, and to conduct a meta-analysis of randomized clinical trials comparing the efficacy of proton pump inhibitor (PPI) vs. RBC with two antibiotics for 1
Hong Lu et al.
European journal of gastroenterology & hepatology, 25(10), 1134-1140 (2013-06-20)
Antimicrobial resistance has continued to undermine many popular anti-Helicobacter pylori therapies. Antibiotic resistance to commonly used anti-H. pylori drugs in China has increased markedly, making China an ideal site to identify regimens that remain effective despite widespread antimicrobial resistance. Bismuth
Ruiguang Ge et al.
Metallomics : integrated biometal science, 4(3), 239-243 (2012-02-24)
Helicobacter pylori causes various gastric diseases, such as gastritis, peptic ulcerations and gastric cancer. Bismuth-based triple or quadruple therapies have been commonly recommended for the treatment of H. pylori infections. Up to now, the molecular mechanisms by which bismuth inhibits
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service